Could an arthritis drug tame OCD? new study investigates

NCT ID NCT04786548

Terminated Symptom relief Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the anti-inflammatory drug celecoxib (Celebrex) can reduce obsessive-compulsive disorder (OCD) symptoms in adults who are already on medication but still struggling. Researchers will use brain scans and blood tests to measure inflammation and see if it predicts who benefits. The trial aims to enroll 21 people and is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: celecoxib (Celebrex)
What this could lead to: If it works, this could point toward a new way to treat OCD by reducing brain inflammation, especially for people who don't respond well to current medications.
What could go wrong: This is a small, early-phase trial that is currently suspended, so results are uncertain. The drug may not reduce OCD symptoms, and side effects from celecoxib are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neuroinflammatory Diseases obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Locations

New York State Psychiatric Institute

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.